We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+11.22%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.3B
AUM Growth
+$1.27B
Cap. Flow
+$755M
Cap. Flow %
7.32%
Top 10 Hldgs %
81.62%
Holding
100
New
12
Increased
23
Reduced
8
Closed
11

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$212M
2
INSM icon
Insmed
INSM
+$178M
3
ALKS icon
Alkermes
ALKS
+$57.4M
4
RVMD icon
Revolution Medicines
RVMD
+$54.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$47.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$22.3M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$17.6M
4
TSVT
2seventy bio
TSVT
+$12.3M
5
BCAX
Bicara Therapeutics
BCAX
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.83B
$44.5M 0.43%
2,118,728
+1,056,605
+99% +$20.3M
NRIX icon
27
Nurix Therapeutics
NRIX
$2.77B
$44.2M 0.43%
3,882,125
– –
ROIV icon
28
Roivant Sciences
ROIV
$26.2B
$42.5M 0.41%
3,767,773
– –
BNTX icon
29
BioNTech
BNTX
$29.3B
$39.3M 0.38%
368,923
+323,892
+719% +$32.7M
TRDA icon
30
Entrada Therapeutics
TRDA
$295M
$32.7M 0.32%
4,865,819
– –
MRUS
31
DELISTED
Merus
MRUS
$30.2M 0.29%
574,377
+350,877
+157% +$16.5M
PRAX icon
32
Praxis Precision Medicines
PRAX
$10.5B
$29M 0.28%
689,488
+357,955
+108% +$13.6M
NTLA icon
33
Intellia Therapeutics
NTLA
$1.8B
$25.1M 0.24%
2,675,674
+2,031,558
+315% +$16.7M
VRDN icon
34
Viridian Therapeutics
VRDN
$2.75B
$24.4M 0.24%
+1,744,406
New +$23.7M
GLUE icon
35
Monte Rosa Therapeutics
GLUE
$1.22B
$22.2M 0.22%
4,916,095
– –
VRNA
36
DELISTED
Verona Pharma
VRNA
$21.2M 0.21%
223,843
– –
PCVX icon
37
Vaxcyte
PCVX
$9.32B
$20.8M 0.2%
640,885
– –
ARGX icon
38
argenx
ARGX
$65B
$20.8M 0.2%
37,760
-40,000
-51% -$23.2M
VERV
39
DELISTED
Verve Therapeutics
VERV
$19M 0.18%
1,691,530
– –
CERS icon
40
Cerus
CERS
$566M
$18.2M 0.18%
12,883,844
-6,467,243
-33% -$8.62M
IRON icon
41
Disc Medicine
IRON
$3.06B
$17.9M 0.17%
337,050
+260,000
+337% +$12.2M
AKRO
42
DELISTED
Akero Therapeutics
AKRO
$17.3M 0.17%
324,630
-224,083
-41% -$10.2M
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$16.1M 0.16%
+125,538
New +$13M
SERA icon
44
Sera Prognostics
SERA
$84.4M
$15.2M 0.15%
5,498,170
– –
ARWR icon
45
Arrowhead Research
ARWR
$12.3B
$14.8M 0.14%
+939,174
New +$13.5M
NGNE icon
46
Neurogene
NGNE
$773M
$14.8M 0.14%
991,691
-494,509
-33% -$7.76M
DNTH icon
47
Dianthus Therapeutics
DNTH
$6.21B
$14.7M 0.14%
+789,759
New +$14.8M
CLDX icon
48
Celldex Therapeutics
CLDX
$3.17B
$13.5M 0.13%
665,370
+417,726
+169% +$8.13M
DBVT
49
DBV Technologies
DBVT
$914M
$13.4M 0.13%
1,461,425
– –
XENE icon
50
Xenon Pharmaceuticals
XENE
$5.88B
$11.6M 0.11%
370,208
+22,800
+7% +$744K
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2025 Portfolio in Review

As of Q2 2025, Julian Baker held 100 positions worth $10.3B, up 14% from $9.04B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker deployed $755M of net new capital in Q2 2025, opening 12 new positions and adding to 23 existing holdings. Its largest new stake was Viridian Therapeutics: 1,744,406 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $23.2M trimmed.

  • Julian Baker's largest Q2 2025 buy was Viridian Therapeutics: 1,744,406 shares worth $24.4M.
  • Julian Baker added most to Summit Therapeutics in Q2 2025, an estimated $212M increase.
  • Julian Baker's biggest Q2 2025 reduction was argenx, cutting an estimated $23.2M.
  • Julian Baker fully exited CRISPR Therapeutics in Q2 2025, selling an estimated $22.3M.
  • Julian Baker's ten largest holdings make up 82% of its $10.3B portfolio in Q2 2025.
  • Julian Baker opened 12 new positions and closed 11 in Q2 2025.
  • Julian Baker's portfolio value rose 14% quarter-over-quarter to $10.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.